3 Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks With a Strong Future Roadmap: Suraksha Diagnostic, India Glycols and Redtape
- October 15, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Suraksha Diagnostic Rs 318.30, P/E 46.05. India Glycols Rs 349.85, P/E 7.58. Redtape Rs 113.46, P/E 25.49. Closing prices of 14 Oct 2026.
Quick Answer
Diagnostic chain, renewable chemical and footwear brand stocks with the clearest long-term roadmaps today include Suraksha Diagnostic in diagnostic and pathology testing through a network of labs and collection centres, India Glycols in glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and Redtape in footwear, apparel and accessories sold through its own brand stores and online channels. FY26 revenue growth was 22.5% at Suraksha Diagnostic, 11.5% at India Glycols and 17.5% at Redtape. P/E stands at 46.05 for Suraksha Diagnostic (industry 62.79), 7.58 for India Glycols (industry 54.53) and 25.49 for Redtape (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Diagnostic chain, renewable chemical and footwear brand stocks give investors exposure to health testing, chemicals and branded footwear for everyday use. Volumes, store additions and margins decide how much of that demand turns into profit.
This list covers three diagnostic chain, renewable chemical and footwear brand stocks: Suraksha Diagnostic for diagnostic and pathology testing through a network of labs and collection centres, India Glycols for glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and Redtape for footwear, apparel and accessories sold through its own brand stores and online channels. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks?
Diagnostic chain, renewable chemical and footwear brand stocks are shares of companies that run diagnostics, make chemicals or sell branded footwear. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three diagnostic chain, renewable chemical and footwear brand stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Suraksha Diagnostic | 318.30 | 1,614 | 46.05 | 62.79 | 13.15% | 0.53 |
| India Glycols | 349.85 | 2,397 | 7.58 | 54.53 | 9.98% | 0.58 |
| Redtape | 113.46 | 6,285 | 25.49 | 66.59 | 23.55% | 0.70 |
Among healthcare and consumer stocks, all three trade at a discount to their industry P/E multiples.
Why Do Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks Have a Strong Roadmap in India?
Diagnostic chain, renewable chemical and footwear brand stocks have a strong roadmap in India because rising health checks, ethanol blending and branded footwear demand keep adding volumes for these firms. Three drivers stand out.
- Preventive health: More people test early and often.
- Renewable chemicals: Ethanol and bio-based chemicals gain policy support.
- Branded footwear: Shoppers shift towards organised brands.
Suraksha Diagnostic: Diagnostic Labs Drive the Pipeline
Suraksha Diagnostic’s roadmap rests on diagnostic and pathology testing through a network of labs and collection centres, with rising health screening supporting test volumes.
Revenue grew from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a 39.1% rise, and FY26 revenue was 22.5% higher than FY25. FY26 net profit rose 1.4% to Rs 31.40 crore. Over four years, net profit rose from Rs 23.75 crore in FY22 to Rs 31.40 crore. In Q1 FY27, revenue grew 20.7% to Rs 88.74 crore, and net profit rose 40.0% to Rs 12.85 crore. Operating margin was 32.01% in FY26 and 35.97% in Q1 FY27 against 33.97% a year earlier.
Debt to equity is 0.53 and return on equity is 13.15%. FY26 operating cash flow was Rs 81.83 crore against capital expenditure of Rs 67.34 crore. Suraksha Diagnostic paid a dividend of Rs 0.05 per share for FY26, a yield of 0.02%. At a P/E of 46.05 against an industry P/E of 62.79, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 35.97% against 32.01% for FY26, so margin stability is the figure to follow as volumes grow.
India Glycols: Green Chemicals and Ethanol Build the Next Leg
India Glycols’ roadmap rests on glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock, with ethanol blending and chemical demand supporting volumes.
Revenue grew from Rs 2,889.84 crore in FY22 to Rs 4,216.34 crore in FY26, a 45.9% rise, and FY26 revenue was 11.5% higher than FY25. FY26 net profit rose 26.8% to Rs 292.76 crore. In Q1 FY27, revenue grew 19.3% to Rs 2,988.82 crore, and net profit rose 32.2% to Rs 96.83 crore. Operating margin was 7.12% in FY26.
Debt to equity is 0.58 and return on equity is 9.98%. FY26 operating cash flow was Rs 769.16 crore against capital expenditure of Rs 823.48 crore. India Glycols paid a dividend of Rs 7.5 per share for FY26, a yield of 2.10%. At a P/E of 7.58 against an industry P/E of 54.53, the stock trades below its industry multiple.
What to watch: The P/E of 7.58 against an industry P/E of 54.53 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Redtape: A Footwear Brand Anchors the Roadmap
Redtape’s roadmap rests on footwear, apparel and accessories sold through its own brand stores and online channels, with store expansion supporting growth.
FY26 revenue was Rs 2,551.61 crore, 17.5% higher than FY25. FY26 net profit rose 41.5% to Rs 240.55 crore. In Q1 FY27, revenue grew 4.8% to Rs 496.42 crore, and net profit rose 15.2% to Rs 44.48 crore. Operating margin was 20.07% in FY26 and 20.50% in Q1 FY27 against 18.56% a year earlier.
Debt to equity is 0.70 and return on equity is 23.55%. FY26 operating cash flow was Rs 174.01 crore against capital expenditure of Rs 85.92 crore. Redtape paid a dividend of Rs 2 per share for FY26, a yield of 1.76%. At a P/E of 25.49 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 20.50% against 20.07% for FY26, so margin stability is the figure to follow as volumes grow.
Best Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks in India: Suraksha Diagnostic vs India Glycols vs Redtape on Key Financials
Among the best diagnostic chain, renewable chemical and footwear brand stocks in India, Suraksha Diagnostic leads on FY26 revenue growth and FY26 operating margin; India Glycols leads on the lowest P/E and dividend yield; Redtape leads on FY26 net profit growth and return on equity. The table puts the numbers side by side.
| Metric | Suraksha Diagnostic | India Glycols | Redtape |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 313.58 | 4,216.34 | 2,551.61 |
| FY26 revenue growth | 22.5% | 11.5% | 17.5% |
| FY26 net profit (Rs Cr) | 31.40 | 292.76 | 240.55 |
| FY26 net profit growth | 1.4% | 26.8% | 41.5% |
| FY26 operating profit margin | 32.01% | 7.12% | 20.07% |
| Q1 FY27 revenue growth (YoY) | 20.7% | 19.3% | 4.8% |
| Q1 FY27 net profit growth (YoY) | 40.0% | 32.2% | 15.2% |
| Return on equity | 13.15% | 9.98% | 23.55% |
| P/E ratio | 46.05 | 7.58 | 25.49 |
| Debt to equity | 0.53 | 0.58 | 0.70 |
| Dividend yield | 0.02% | 2.10% | 1.76% |
| FY26 operating cash flow (Rs Cr) | 81.83 | 769.16 | 174.01 |
Healthcare and consumer earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen diagnostic chain, renewable chemical and footwear brand stocks and shortlist diagnostic chain, renewable chemical and footwear brand stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Suraksha Diagnostic, India Glycols and Redtape live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare and consumer stocks cover diagnostics, renewable chemicals and footwear. Suraksha Diagnostic leads on FY26 revenue growth and FY26 operating margin; India Glycols leads on the lowest P/E and dividend yield; Redtape leads on FY26 net profit growth and return on equity.
Across diagnostic chain, renewable chemical and footwear brand stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the diagnostic chain, renewable chemical and footwear brand stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Diagnostic Chain, Renewable Chemical and Footwear Brand Stocks
Which are the best diagnostic chain, renewable chemical and footwear brand stocks in India with a strong roadmap?
Ans. Suraksha Diagnostic, India Glycols and Redtape stand out for their roadmaps in diagnostics, renewable chemicals and footwear. FY26 revenue growth was 22.5% at Suraksha Diagnostic, 11.5% at India Glycols and 17.5% at Redtape, and return on equity ranges from 9.98% to 23.55%.
Is Suraksha Diagnostic a good stock to buy now?
Ans. Suraksha Diagnostic has a debt to equity ratio of 0.53, a return on equity of 13.15% and a P/E of 46.05 against an industry P/E of 62.79. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Suraksha Diagnostic, India Glycols and Redtape?
Ans. The P/E ratio is 46.05 for Suraksha Diagnostic (industry 62.79), 7.58 for India Glycols (industry 54.53) and 25.49 for Redtape (industry 66.59). All of them trade below the industry multiple.
Which of these diagnostic chain, renewable chemical and footwear brand stocks has the highest return on equity?
Ans. Redtape has the highest return on equity at 23.55%, followed by Suraksha Diagnostic at 13.15% and India Glycols at 9.98%.
What are the risks of investing in diagnostic chain, renewable chemical and footwear brand stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Suraksha Diagnostic, India Glycols and Redtape perform in Q1 FY27?
Ans. Suraksha Diagnostic reported revenue of Rs 88.74 crore, up 20.7% year on year, and net profit rose 40.0% to Rs 12.85 crore. India Glycols reported revenue of Rs 2,988.82 crore, up 19.3% year on year, and net profit rose 32.2% to Rs 96.83 crore. Redtape reported revenue of Rs 496.42 crore, up 4.8% year on year, and net profit rose 15.2% to Rs 44.48 crore.
Do diagnostic chain, renewable chemical and footwear brand stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.02% for Suraksha Diagnostic, 2.10% for India Glycols and 1.76% for Redtape, based on dividends declared for FY26.
How can I invest in diagnostic chain, renewable chemical and footwear brand stocks in India?
Ans. You can buy diagnostic chain, renewable chemical and footwear brand stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
